細胞和基因治療製造市場規模、佔有率和成長分析：按治療方法、製造流程、規模、最終用戶和地區分類—2026-2033年產業預測

2024 年全球細胞和基因治療製造市場價值為 85.2 億美元，預計到 2025 年將成長至 97.6 億美元，到 2033 年將成長至 288.5 億美元，在預測期（2026-2033 年）內複合年成長率為 14.52%。

在科學創新和未被滿足的醫療需求的驅動下，全球細胞和基因治療製造業發生了顯著變化。目前，該市場格局的特點是：符合良好生產規範 (GMP) 的生物製造程序，涵蓋自體和異體療法，以及旨在為癌症和罕見遺傳疾病提供持續單劑量療法的病毒載體和基因編輯產品。從學術研究機構向符合 GMP 標準的契約製造製造商的轉變，推動了 CAR-T 細胞療法生產的擴展。此外，使用腺結合病毒載體的療法正從小眾臨床試驗轉向針對大規模人口的研究，這需要大量的資源投入。為了滿足不斷成長的需求和應對個人化療法的複雜性，申辦者越來越依賴合約研發生產機構 (CDMO) 和模組化設施，從而在提高生產能力的同時，最大限度地降低污染風險。

全球細胞和基因治療製造市場的成長要素

全球細胞和基因治療生產市場的發展主要得益於生物製程技術的顯著進步，這些技術提高了可擴展性、一致性和生產效率。這些創新使得從實驗室環境到商業化生產的過渡更有效率。改進的生物反應器設計、自動化細胞處理和先進的製程控制降低了變異性，並提高了批次可靠性。因此，契約製造製造商和創新研發公司正擴大採用這些技術。這些進步降低了營運複雜性，使生產能力與臨床需求相匹配，並鼓勵對產能擴張進行投資，使企業能夠開展更具挑戰性的治療項目，這些項目需要可靠且可重複的生產流程。

全球細胞和基因治療製造市場的限制因素

全球細胞和基因治療生產市場面臨嚴峻挑戰，這主要是由於專用設施、先進設備、熟練人員和嚴格的品管體係等相關高成本居高不下。這些財務壁壘嚴重阻礙了許多企業發展或擴大其生產能力。建造符合規範的無塵室和採購專用材料所需的大量資金增加了預算負擔，這往往會阻礙規模小規模的創新企業推進候選產品的研發。此外，這些成本壓力限制了生產的柔軟性，迫使企業優先考慮特定項目。因此，能夠以所需規模和品質生產的治療方法數量有限，導致市場成長放緩。

全球細胞和基因治療製造市場趨勢

全球細胞和基因治療生產市場正呈現出模組化設施擴張的顯著趨勢，其特點是採用模組化和預製設計，從而提高生產速度和效率。這種變革性的方法不僅能夠快速重新配置以適應不同的治療方法，而且還能進一步促進申辦者和專業契約製造製造商之間的合作。透過推廣即插即用的工藝整合，它簡化了維修，從而有效應對了技術過時的挑戰。此外，模組化策略因其靈活的驗證途徑和可擴展的生產能力，能夠跟上不斷發展的治療解決方案趨勢，因此正獲得投資者和監管機構的支持。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球細胞和基因治療製造市場規模：按治療類型分類

• 細胞療法生產
  • CAR-T
  • NK細胞
  • 幹細胞
• 基因治療生產

全球細胞和基因治療製造市場規模：按工藝分類

• 上游生物程序
• 下游淨化
• 填充和精加工

全球細胞和基因治療製造市場規模：按市場規模分類

• 臨床量表
• 商業規模

全球細胞和基因治療製造市場規模：按最終用戶分類

• 製藥和生物技術公司
• CDMO
• 大學醫院

全球細胞和基因治療製造市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Lonza Group（Cocoon Platform）
• Catalent Inc.
• Thermo Fisher Scientific
• WuXi Advanced Therapies
• Fujifilm Diosynth Biotechnologies
• Sartorius AG
• Cytiva（Danaher）
• Oxford Biomedica plc
• Andelyn Biosciences
• Cellipont Bioservices
• PCT（Hitachi）
• Novatek International
• AGC Biologics
• Orion Pharma
• Kite Pharma（Gilead）
• Novartis（AveXis）
• Bristol Myers Squibb（Juno）
• Samsung Biologics
• Rentschler Biopharma
• KBI Biopharma

結論與建議

Global Cell And Gene Therapy Manufacturing Market size was valued at USD 8.52 Billion in 2024 and is poised to grow from USD 9.76 Billion in 2025 to USD 28.85 Billion by 2033, growing at a CAGR of 14.52% during the forecast period (2026-2033).

The global cell and gene therapy manufacturing landscape has evolved significantly, driven by scientific innovation and unmet clinical needs. Currently, the market is characterized by Good Manufacturing Practice (GMP) biomanufacturing tailored for autologous and allogeneic therapies, alongside viral vector and genome-edited products aimed at providing lasting, single-administration treatments for cancer and rare genetic conditions. The shift from academic labs to GMP contract manufacturers has facilitated the broader production of CAR T-cell therapies. Additionally, adeno-associated virus vectors have transitioned from niche trials to studies targeting larger populations, necessitating substantial resource investments. To meet surging demand and the complexities of personalized treatments, sponsors increasingly rely on contract development and manufacturing organizations (CDMOs) and modular facilities, enhancing throughput while minimizing contamination risks.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cell And Gene Therapy Manufacturing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cell And Gene Therapy Manufacturing Market Segments Analysis

Global cell and gene therapy manufacturing market is segmented by therapy type, process, scale, end-user and region. Based on therapy type, the market is segmented into Cell Therapy Manufacturing and Gene Therapy Manufacturing. Based on process, the market is segmented into Upstream Bioprocessing, Downstream Purification and Fill-Finish. Based on scale, the market is segmented into Clinical-Scale and Commercial-Scale. Based on end-user, the market is segmented into Pharma & Biotech Companies, CDMOs and Academic Medical Centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Cell And Gene Therapy Manufacturing Market

The global market for cell and gene therapy manufacturing is being propelled by significant advancements in bioprocess technologies, which enhance scalability, consistency, and throughput. These innovations facilitate the transition of products from laboratory settings to commercial production with greater efficiency. Enhanced bioreactor designs, automation in cell handling, and refined process controls lead to reduced variability and increased batch reliability. As a result, contract manufacturers and innovative developers are more likely to adopt these technologies. This progress diminishes operational complexity, aligns manufacturing capacity with clinical demand, and stimulates investment in capacity expansion, encouraging firms to pursue more ambitious therapeutic projects that require dependable and reproducible manufacturing processes.

Restraints in the Global Cell And Gene Therapy Manufacturing Market

The Global Cell and Gene Therapy Manufacturing market faces notable challenges due to the consistently high expenses linked to specialized facilities, advanced equipment, skilled personnel, and rigorous quality control systems. These financial hurdles significantly hinder many organizations from developing or enhancing their manufacturing capabilities. The substantial capital required for building compliant cleanrooms and obtaining specialized materials adds budgetary strain, often discouraging smaller innovators from advancing their product candidates. Moreover, these cost pressures can restrict production flexibility, compelling companies to prioritize certain programs, which ultimately slows market growth by limiting the number of therapies that can be produced at the necessary scale and quality.

Market Trends of the Global Cell And Gene Therapy Manufacturing Market

The Global Cell and Gene Therapy Manufacturing market is witnessing a significant trend towards modular facility expansion, characterized by the adoption of modular and prefabricated designs that enhance the speed and efficiency of production capability. This transformative approach not only enables rapid reconfiguration for varied therapies but also fosters greater collaboration between sponsors and specialized contract manufacturers. By promoting plug-and-play process integration, it addresses the challenges of technology obsolescence through simplified retrofitting. Furthermore, the modular strategy is gaining favor among investors and regulators alike, as it offers flexible validation pathways and scalable capacities that align with the continuously evolving landscape of therapeutic solutions.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Cell And Gene Therapy Manufacturing Market Size by Therapy Type & CAGR (2026-2033)

• Market Overview
• Cell Therapy Manufacturing
  • CAR-T
  • NK Cell
  • Stem Cell
• Gene Therapy Manufacturing

Global Cell And Gene Therapy Manufacturing Market Size by Process & CAGR (2026-2033)

• Market Overview
• Upstream Bioprocessing
• Downstream Purification
• Fill-Finish

Global Cell And Gene Therapy Manufacturing Market Size by Scale & CAGR (2026-2033)

• Market Overview
• Clinical-Scale
• Commercial-Scale

Global Cell And Gene Therapy Manufacturing Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Pharma & Biotech Companies
• CDMOs
• Academic Medical Centers

Global Cell And Gene Therapy Manufacturing Market Size & CAGR (2026-2033)

• North America (Therapy Type, Process, Scale, End-User)
  • US
  • Canada
• Europe (Therapy Type, Process, Scale, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapy Type, Process, Scale, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapy Type, Process, Scale, End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapy Type, Process, Scale, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Lonza Group (Cocoon Platform)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Catalent Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi Advanced Therapies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fujifilm Diosynth Biotechnologies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sartorius AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cytiva (Danaher)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oxford Biomedica plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Andelyn Biosciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cellipont Bioservices
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PCT (Hitachi)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novatek International
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AGC Biologics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Orion Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kite Pharma (Gilead)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (AveXis)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (Juno)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Biologics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Rentschler Biopharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• KBI Biopharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations